Takeda Pharmaceutical (TAK) Net Margin (2017 - 2026)

Takeda Pharmaceutical's Net Margin history runs 10 years deep, the most recent figure standing at 2.22% for Q1 2026.

• In Q1 2026, Net Margin fell 2514.0% year-over-year to 2.22%; the TTM figure through Mar 2026 stood at 15.1% (down 189.0% YoY), while the FY2026 annual figure was 4.26%, up 190.0% from the prior year.
• Net Margin was 2.22% for Q1 2026 at Takeda Pharmaceutical, down from 12.85% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 23.44% in Q3 2023 to a low of 2.22% in Q1 2026.
• Historically, Net Margin has averaged 12.08% across 5 years, with a median of 10.86% in 2022.
• The sharpest annual moves came in 2022 and 2023: Net Margin plunged 2676 bps in 2022, then jumped 2322 bps in 2023.
• A 5-year view of Net Margin shows it stood at 10.86% in 2022, then surged by 39 bps to 15.15% in 2023, then slipped by 29 bps to 10.76% in 2024, then increased by 19 bps to 12.85% in 2025, then slumped by 117 bps to 2.22% in 2026.
• The last three Net Margin figures came in at 2.22% (Q1 2026), 12.85% (Q4 2025), and 19.81% (Q3 2025), per Business Quant data.